About: Optimal AntiPlatelet therapy for prevention of gastrointestinal injury evaluated by Ankon magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Optimal AntiPlatelet therapy for prevention of gastrointestinal injury evaluated by Ankon magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Optimal AntiPlatelet therapy for prevention of gastrointestinal injury evaluated by Ankon magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial
Creator	Li, Jing Li, Yi Xu, Kai Li, Zhaoshen Han, Xiao Stone, Gregg Han, Yaling Liao, Zhuan Wang, Xiaozeng Bao, Dan Wang, Heyang
Source	Elsevier; Medline; PMC
abstract	Abstract Background Gastrointestinal injury is a common complication in patients treated with antiplatelet agents after percutaneous coronary intervention (PCI). However, the effects of different antiplatelet regimens on the incidence and severity of gastrointestinal injury have not been well studied, principally due to the lack of a low-risk sensitive and accurate detection system. Trial design. OPT-PEACE is a multicenter, randomized, double-blind, placebo-controlled trial. Gastrointestinal injury will be evaluated with the ANKON magnetically controlled capsule endoscopy system (AMCE), a minimally invasive approach for detecting mucosal lesions in the stomach, duodenum and small intestine. Patients without AMCE-detected gastrointestinal erosions, ulceration or bleeding after drug-eluting stent implantation are enrolled and treated with open-label aspirin (100mg/day) plus clopidogrel (75mg/day) for 6months. Thereafter, 480 event-free patients will undergo repeat AMCE and are randomly assigned in a 1:1:1 ratio to receive aspirin plus clopidogrel, aspirin plus placebo or clopidogrel plus placebo for an additional 6months. A final AMCE is performed at 12months. The primary endpoint is the incidence of gastric or intestinal mucosal lesions (erosions, ulceration or bleeding) within 12months after enrollment. Conclusions OPT-PEACE is the first study to investigate the incidence and severity of gastrointestinal injury in patients receiving different antiplatelet therapy regimens after stent implantation. This trial will inform clinical decision-making for personalized antiplatelet therapy post-PCI.
has issue date	2020-06-15(xsd:dateTime)
bibo:doi	10.1016/j.ahj.2020.06.004
bibo:pmid	32745734
has license	els-covid
sha1sum (hex)	75a766a067e2a2cd1ad2cb18d956e808bbb49d90
schema:url	https://doi.org/10.1016/j.ahj.2020.06.004
resource representing a document's title	Optimal AntiPlatelet therapy for prevention of gastrointestinal injury evaluated by Ankon magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial
has PubMed Central identifier	PMC7294257
has PubMed identifier	32745734
schema:publication	Am Heart J
resource representing a document's body	covid:75a766a067e2a2cd1ad2cb18d956e808bbb49d90#body_text
is schema:about of	named entity 'patients' named entity 'sensitive' named entity 'injury' named entity 'Gastrointestinal' named entity 'Rationale' named entity 'prevention' named entity 'PRE' named entity 'Journal' named entity 'antiplatelet agents' named entity 'common' named entity 'PCI' named entity 'Injury' named entity 'Gastrointestinal' named entity 'antiplatelet agents' named entity 'PCI' named entity 'primary endpoint' named entity 'revascularization' named entity 'cut-off' named entity 'PCI' named entity 'gastrointestinal bleeding' named entity 'gastrointestinal ulceration' named entity 'randomization' named entity 'platelet' named entity 'coronary artery disease' named entity 'cardiac death' named entity 'small intestine' named entity 'dual antiplatelet therapy' named entity 'stomach' named entity 'cardiologists' named entity 'depth of field' named entity 'PCI' named entity 'Menarini Group' named entity 'mucosa' named entity 'eGFR' named entity 'pros and cons' named entity 'revascularization' named entity 'DAPT' named entity 'excretion' named entity 'gastrointestinal bleeding' named entity 'acute coronary syndromes' named entity 'DSMB' named entity 'dysphagia' named entity 'clinical indication' named entity 'diabetes mellitus' named entity 'vomiting' named entity 'digestive tract' named entity 'aspirin' named entity 'clopidogrel' named entity 'Gastrointestinal symptoms' named entity 'chronic kidney disease' named entity 'PCI' named entity 'excreted' named entity 'Subgroup analysis' named entity 'Primary endpoint' named entity 'adverse events' named entity 'secondary endpoints' named entity 'antiplatelet therapy' named entity '40 minutes' named entity 'Helicobacter Pylori' named entity 'DAPT' named entity 'endoscopic capsule' named entity 'randomization' named entity 'non-compliance' named entity 'stomach' named entity 'endoscopic' named entity 'gastric mucosa' named entity 'adverse events' named entity 'infection status' named entity 'randomization' named entity 'placebo' named entity 'DAPT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software